Sarepta Therapeutics (NASDAQ:SRPT) Given New $50.00 Price Target at BMO Capital Markets

Sarepta Therapeutics (NASDAQ:SRPT) had its target price lifted by analysts at BMO Capital Markets from $25.00 to $50.00 in a report released on Tuesday,Benzinga reports. The firm currently has a “market perform” rating on the biotechnology company’s stock. BMO Capital Markets’ target price suggests a potential upside of 198.51% from the stock’s current price.

A number of other research analysts also recently issued reports on the stock. Piper Sandler upped their target price on shares of Sarepta Therapeutics to $15.00 and gave the company a “neutral” rating in a research report on Tuesday. Royal Bank Of Canada cut their target price on shares of Sarepta Therapeutics from $25.00 to $23.00 and set a “sector perform” rating on the stock in a research report on Thursday, July 17th. Cantor Fitzgerald restated a “neutral” rating on shares of Sarepta Therapeutics in a research report on Monday, June 16th. UBS Group restated a “neutral” rating on shares of Sarepta Therapeutics in a report on Monday, July 21st. Finally, William Blair restated a “market perform” rating on shares of Sarepta Therapeutics in a report on Thursday, July 17th. Six equities research analysts have rated the stock with a sell rating, sixteen have issued a hold rating and eight have given a buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $49.12.

Sarepta Therapeutics Stock Performance

Shares of Sarepta Therapeutics stock opened at $16.75 on Tuesday. The firm has a 50 day simple moving average of $24.69 and a 200 day simple moving average of $62.20. The firm has a market cap of $1.65 billion, a P/E ratio of -6.23 and a beta of 0.45. Sarepta Therapeutics has a fifty-two week low of $10.41 and a fifty-two week high of $145.00. The company has a debt-to-equity ratio of 1.00, a current ratio of 4.02 and a quick ratio of 2.46.

Sarepta Therapeutics (NASDAQ:SRPT) last released its earnings results on Tuesday, May 6th. The biotechnology company reported ($3.42) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $2.20 by ($5.62). Sarepta Therapeutics had a negative net margin of 11.12% and a negative return on equity of 14.88%. The business had revenue of $744.86 million for the quarter, compared to analyst estimates of $685.75 million. During the same quarter in the previous year, the company posted $0.73 earnings per share. The business’s revenue for the quarter was up 80.2% on a year-over-year basis. Sell-side analysts predict that Sarepta Therapeutics will post 2.67 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the stock. Commonwealth Equity Services LLC increased its holdings in shares of Sarepta Therapeutics by 22.1% during the 4th quarter. Commonwealth Equity Services LLC now owns 6,357 shares of the biotechnology company’s stock worth $773,000 after acquiring an additional 1,151 shares during the last quarter. Sei Investments Co. lifted its position in shares of Sarepta Therapeutics by 31.7% during the 4th quarter. Sei Investments Co. now owns 23,935 shares of the biotechnology company’s stock valued at $2,910,000 after acquiring an additional 5,764 shares during the period. LPL Financial LLC lifted its position in shares of Sarepta Therapeutics by 12.4% during the 4th quarter. LPL Financial LLC now owns 53,438 shares of the biotechnology company’s stock valued at $6,497,000 after acquiring an additional 5,895 shares during the period. Prudential Financial Inc. lifted its position in shares of Sarepta Therapeutics by 14.7% during the 4th quarter. Prudential Financial Inc. now owns 27,965 shares of the biotechnology company’s stock valued at $3,400,000 after acquiring an additional 3,574 shares during the period. Finally, Mitsubishi UFJ Asset Management Co. Ltd. grew its position in Sarepta Therapeutics by 11.1% in the fourth quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 2,429 shares of the biotechnology company’s stock valued at $307,000 after acquiring an additional 243 shares during the last quarter. Institutional investors and hedge funds own 86.68% of the company’s stock.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.